Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 2008;168:826-831. Data from the Group Health Atrial ...

Alendronate (Fosamax) reduces fracture rates among women with osteoporosis, usually defined as bone mineral density T-scores lower than -2.5. However, the benefit of alendronate in women with ...

Please provide your email address to receive an email when new articles are posted on . Adults with overweight or obesity, but not type 2 diabetes, lost 14.9% of their body weight after 46 weeks of ...

Romosozumab plus alendronate vs alendronate alone was associated with improved lumbar spine BMD among postmenopausal women with T2D and osteoporosis. Romosozumab followed by alendronate treatment ...

Denosumab, a fully human antibody against receptor activator of NF-κB ligand, and alendronate, a bisphosphonate, have different mechanisms of action in preventing structural decay of bone in patients ...

Compared with alendronate, teriparatide was associated with significantly greater pain reduction and better quality of life among postmenopausal women with osteoporosis. Teriparatide has a favorable ...

Alendronate is frequently used to treat postmenopausal osteoporosis; however, the effects of long-term treatment on BMD, bone turnover, and fracture risk remain poorly characterized. The Fracture ...

Please provide your email address to receive an email when new articles are posted on . “Glucocorticoids are the mainstay of treatment of autoimmune inflammatory diseases, but it is also the leading ...

Romosozumab is a monoclonal antibody that binds to and inhibits sclerostin, increases bone formation, and decreases bone resorption. We enrolled 4093 postmenopausal women with osteoporosis and a ...

Statin pills for patient with high cholesterol Decrease in bone mass is common in the first 6 to 12 months after kidney transplantation. Long-term use of alendronate, a bisphosphonate, may slow bone ...

Giving 10mg per day of the bisphosphate drug alendronate to women after their menopause can help prevent loss of bone mass, reducing their risk of fractures, a Cochrane Review has found. This finding ...

Giving 10mg per day of the bisphosphate drug alendronate to women after their menopause can help prevent loss of bone mass, reducing their risk of fractures, a Cochrane Review has found. This finding ...